PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity

Carreño, Juan Manuel; Pérez-Shibayama, Christian; Gil‐Cruz, Cristina; Printz, Andrea; Pastelín, Rodolfo; Isibasí, Armando; Chariatte, Dominic; Tanoue, Yutaka; López-Macı́as, Constantino; Gander, Bruno; Ludewig, Burkhard

doi:10.1016/j.vaccine.2016.05.036

Cited by 20 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For several antigens studied, including plasmid DNA and protein antigen payloads, single administration significantly improved long-term IgA and IgG antibody titers in comparison to soluble antigen, attributed to sustained antigen release mediated by particles [117–120]. …”

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

319

275

View full text Add to dashboard Cite

While vaccination remains the most cost effective strategy for disease prevention, communicable diseases persist as the second leading cause of death worldwide. There is a need to design safe, novel vaccine delivery methods to protect against unaddressed and emerging diseases. Development of vaccines administered orally is preferable to traditional injection-based formulations for numerous reasons including improved safety and compliance, and easier manufacturing and administration. Additionally, the oral route enables stimulation of humoral and cellular immune responses at both systemic and mucosal sites to establish broader and long-lasting protection. However, oral delivery is challenging, requiring formulations to overcome the harsh gastrointestinal (GI) environment and avoid tolerance induction to achieve effective protection. Here we address the rationale for oral vaccines, including key biological and physicochemical considerations for next-generation oral vaccine design.

show abstract

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

319

275

View full text Add to dashboard Cite

show abstract

“…Encapsulation of NOD-1 and NOD-2 ligands, followed by adsorption of the HIV-1 p24 gag protein in PLA NPs, yields a vaccine formulation able to induce human monocytederived DC activation and T cell proliferation in vitro and a p24-specific mucosal and systemic IgA and IgG secretion after oral mouse immunization (221). In the context of S. Typhi Omps, encapsulation in PLGA beads increases specific B cell responses in PPs and MLNs of orally immunized mice compared to Omps alone, suggesting the versatility of this delivery system (222). Outside chemically based delivery systems, viral and bacterial Ags expressed in safe natural carriers such as probiotic strains generate specific local and systemic protective immunity observed in case of S. Typhimurium infection in mice when fed orally (223)(224)(225)(226).…”

Section: Delivery Vehicles For Mucosal Vaccinationmentioning

confidence: 99%

Vaccination against Salmonella Infection: the Mucosal Way

Gayet¹,

Bioley²,

Rochereau³

et al. 2017

Microbiol Mol Biol Rev

View full text Add to dashboard Cite

subspecies includes several serovars infecting both humans and other animals and leading to typhoid fever or gastroenteritis. The high prevalence of associated morbidity and mortality, together with an increased emergence of multidrug-resistant strains, is a current global health issue that has prompted the development of vaccination strategies that confer protection against most serovars. Currently available systemic vaccine approaches have major limitations, including a reduced effectiveness in young children and a lack of cross-protection among different strains. Having studied host-pathogen interactions, microbiologists and immunologists argue in favor of topical gastrointestinal administration for improvement in vaccine efficacy. Here, recent advances in this field are summarized, including mechanisms of bacterial uptake at the intestinal epithelium, the assessment of protective host immunity, and improved animal models that closely mimic infection in humans. The pros and cons of existing vaccines are presented, along with recent progress made with novel formulations. Finally, new candidate antigens and their relevance in the refined design of anti- vaccines are discussed, along with antigen vectorization strategies such as nanoparticles or secretory immunoglobulins, with a focus on potentiating mucosal vaccine efficacy.

show abstract

“…PLGA biodegradable polymers have been commercially developed, obtaining materials with different mechanical properties [ 5 ]. They have been approved by the Food and Drug Administration for human use [ 6 – 9 ], being applied in locally implanted medical devices, scaffolds [ 8 , 10 ], and as biodegradable carrier for the delivery [ 11 , 12 ] of different therapeutic agents such as proteins, DNA, peptides, among others [ 12 , 13 ]. In fact, the PLGA is the most extensively studied and used polymer for delivery applications [ 14 ], taking into account its biodegradability and biocompatibility properties [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Statistical degradation modelling of Poly(D,L-lactide-co-glycolide) copolymers for bioscaffold applications

et al. 2018

View full text Add to dashboard Cite

This methodology permits to simulate the performance of different Poly(D,L-lactide-co-glycolide) copolymer formulations (PDLGA) in the human body, to identify the more influencing variables on hydrolytic degradation and, thus, to estimate biopolymer degradation level. The PDLGA characteristic degradation trends, caused by hydrolysis processes, have been studied to define their future biomedical applications as dental scaffolds. For this purpose, the mass loss, pH, glass transition temperature (Tg) and absorbed water mass of the different biopolymers have been obtained from samples into a phosphate-buffered saline solution (PBS) with initial pH of 7.4, at 37°C (human body conditions). The mass loss has been defined as the variable that characterize the biopolymer degradation level. Its dependence relationship with respect to time, pH and biopolymer formulation has been modelled using statistical learning tools. Namely, generalized additive models (GAM) and nonlinear mixed-effects regression with logistic and asymptotic functions have been applied. GAM model provides information about the relevant variables and the parametric functions that relate mass loss, pH and time. Mixed effects are introduced to model and estimate the degradation properties, and to compare the PDLGA biopolymer populations. The degradation path for each polymer formulation has been estimated and compared with respect to the others for helping to use the proper polymer for each specific medical application, performing selection criteria. It was found that the mass loss differences in PDLGA copolymers are strongly related with the way the pH decay versus time, due to carboxylic acid groups formation. This may occur in those environments in which the degradation products remain relatively confined with the non degraded mass. This is the case emulated with the present experimental procedure. The results show that PDLGA polymers degradation degree, in terms of half life and degradation rate, is increasing when acid termination is included, when DL-lactide molar ratio is reduced, decreasing the midpoint viscosity, or when glycolide is not included.

show abstract

PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity

Cited by 20 publications

References 31 publications

Current state and challenges in developing oral vaccines

Current state and challenges in developing oral vaccines

Vaccination against Salmonella Infection: the Mucosal Way

Statistical degradation modelling of Poly(D,L-lactide-co-glycolide) copolymers for bioscaffold applications

Contact Info

Product

Resources

About